STAAR Surgical Company (NASDAQ:STAA – Get Free Report) has received an average rating of “Hold” from the ten research firms that are presently covering the company, MarketBeat.com reports. Ten equities research analysts have rated the stock with a hold recommendation. The average 1-year target price among brokers that have issued a report on the stock in the last year is $20.6667.
Several equities analysts have recently weighed in on STAA shares. Mizuho raised their price target on shares of STAAR Surgical from $17.00 to $18.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 16th. Piper Sandler raised shares of STAAR Surgical to a “hold” rating in a research note on Wednesday, June 18th. Canaccord Genuity Group lifted their target price on shares of STAAR Surgical from $20.00 to $28.00 and gave the stock a “hold” rating in a research note on Wednesday, August 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a research note on Wednesday, May 21st. Finally, Stifel Nicolaus set a $28.00 target price on shares of STAAR Surgical and gave the stock a “hold” rating in a research note on Thursday, August 7th.
Check Out Our Latest Stock Report on STAAR Surgical
Hedge Funds Weigh In On STAAR Surgical
STAAR Surgical Trading Down 1.4%
NASDAQ:STAA opened at $27.70 on Friday. The company’s 50-day moving average price is $23.54 and its 200-day moving average price is $19.66. The company has a market cap of $1.37 billion, a P/E ratio of -14.35 and a beta of 0.74. STAAR Surgical has a twelve month low of $13.50 and a twelve month high of $38.60.
STAAR Surgical declared that its Board of Directors has approved a share repurchase program on Friday, May 16th that permits the company to buyback $30.00 million in outstanding shares. This buyback authorization permits the medical instruments supplier to purchase up to 3.2% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its shares are undervalued.
About STAAR Surgical
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Read More
- Five stocks we like better than STAAR Surgical
- Investing In Automotive Stocks
- Tesla’s U.S. Market Is At An 8-Year Low… How Bad Could It Get?
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Congress: The Biggest Trades Impacting Markets Today
- How to find penny stocks to invest and tradeĀ
- 3 Companies Boosting Buybacks While Others Pull Back
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.